The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Abstract
Antibody antagonists of the insulinotropic receptor GIPR prevent weight gain in obese animal models, and the effect is enhanced by GLP-1R agonists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combined, the SURPASS and SURMOUNT trials have verified the safety of tirzepatide to be consistent with GLP-1R agonists, along with its enhanced efficacy at maximal doses of 5, 10 and 15 mg (Table 1)132-136,143,145-147”
From Transforming obesity: The advancement of multi-receptor drugs (2024) · cites this paper as [146]
In the citing paper
“agonists and antagonists of the GIP receptor (GIPR) are currently in development, both of which have paradoxically demonstrated the ability to potentiate the weight reduction of GLP-1R agonists in preclinical models [[32], [33], [34], [35], [36], [37]]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [33]
In the citing paper
“Neutralizing GIPR antibodies, which are presumably sequestered to the periphery, reduce body weight in an independent manner to food intake and modify energetic substrate utilization in vivo [33]”
From Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice (2022) · cites this paper as [33]
In the citing paper
“The combination of an anti-GIPR monoclonal antibody (mAb) and a GLP-1RA has been shown to mediate more pronounced weight loss than either agent alone in preclinical obesity models33.”
From A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings (2024) · cites this paper as [33]
In the citing paper
“However, it has been shown in animal models that GIP RAs potentiates GLP-1-induced weight loss and reduces food intake [164,165].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [165]
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
How good are my data and what is the resolution?
Evans, P. R., & Murshudov, G. N. (2013) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444913000061 · Cited by 4,697
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Postic, C., Shiota, M., Niswender, K. D., Jetton, T. L., Chen, Y., Moates, J. M., Shelton, K. D., Lindner, J., Cherrington, A. D., & Magnuson, M. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.1.305 · Cited by 1,302
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 4×
“This finding has not been observed in GIPR KO mouse models (9, 22, 32) or in other therapies targeting the GIP/GIPR axis (31).”
BackgroundMethodResultInfluential
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“However, controversy still exists as to whether it is best to therapeutically promote or inhibit GIP action for beneficial effects on glycemic control and body weight [929e931] as both GIPR agonists [932] and antagonists [933,934] have decreased body weight in preclinical studies as individual treatments, but also to…”
BackgroundTirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541
“In the presence of HSA, TZP right-shifts 81-fold (n = 5), while the potency of GLP-1(7-36) is unaltered (n = 24).”
InfluentialHow May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383
Metadata
- Authors
- Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., Lu, S.-C., Kurzeja, R. J. M., Sivits, G., Lin, J., Chen, Q., Wang, Z., Thibault, S. A., Abbott, C. M., Meng, T., Clavette, B., Murawsky, C. M., Foltz, I. N., Rottman, J. B., Hale, C., Véniant, M. M., & Lloyd, D. J.
- Affiliations
- Amgen (United States) (US)
- Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
- Amgen Research, Department of Therapeutic Discovery, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA.
- Amgen Research, Department of Therapeutic Discovery, Amgen Inc., 7990 Enterprise Street, Burnaby, BC V5A 1V7, Canada.
- Corresponding author
- Killion, Elizabeth A.
- Wang, Jinghong
- Yie, Junming
- Lloyd, David J.
- ORCID
- Killion, Elizabeth A.
- Wang, Jinghong
- Yie, Junming
- Shi, Stone D.-H.
- Bates, Darren
- Min, Xiaoshan
- Komorowski, Renee
- Deng, Liying
- Lu, Shu-Chen
- Kurzeja, Robert J. M.
- Sivits, Glenn
- Chen, Qing
- Wang, Zhulun
- Thibault, Stephen A.
- Abbott, Christina M.
- Clavette, Brandon
- Murawsky, Christopher M.
- Rottman, James B.
- Hale, Clarence
- Véniant, Murielle M.
- Lloyd, David J.
- Venue
- Science Translational Medicine
- Published
- 2018-12-19
- Volume
- 10
- Issue
- 472
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2904833368
- Cited by
- 237
- References
- 42
- Citations by year
- 2026: 32 · 2025: 33 · 2024: 33 · 2023: 28 · 2022: 31 · 2021: 31 · 2020: 20 · 2019: 27
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen Inc
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GIP receptor antagonist, obesity, diet-induced obesity, GLP-1 receptor agonists, combination therapy, weight loss, dietary intake, respiratory exchange ratio, non-human primates, pancreatic beta cells, obesity treatment
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antibodies, Diet, Drug Therapy, Combination, Glucagon-Like Peptides, Feeding Behavior, Gastric Inhibitory Polypeptide, Humans, Immunoglobulin Fc Fragments, Mice, Obese, Obesity, Primates, Receptors, Gastrointestinal Hormone, Recombinant Fusion Proteins, Respiration, Weight Gain, Weight Loss, Adipocytes, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. https://app.cochat.ai/papers/10.1126/scitranslmed.aat3392
- The paper
- Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., Lu, S.-C., Kurzeja, R. J. M., Sivits, G., Lin, J., Chen, Q., Wang, Z., Thibault, S. A., Abbott, C. M., Meng, T., . . . Lloyd, D. J. (2018). Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aat3392
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.